Emerging Issues in AAV-Mediated In Vivo Gene Therapy

In recent years, the number of clinical trials in which adeno-associated virus (AAV) vectors have been used for in vivo gene transfer has steadily increased. The excellent safety profile, together with the high efficiency of transduction of a broad range of target tissues, has established AAV vectors as the platform of choice for in vivo gene therapy. Successful application of the AAV technology has also been achieved in the clinic for a variety of conditions, including coagulation disorders, inherited blindness, and neurodegenerative diseases, among others. Clinical translation of novel and effective “therapeutic products” is, however, a long process that involves several cycles of iterations from bench to bedside that are required to address issues encountered during drug development. For the AAV vector gene transfer technology, several hurdles have emerged in both preclinical studies and clinical trials; addressing these issues will allow in the future to expand the scope of AAV gene transfer as a therapeutic modality for a variety of human diseases. In this review, we will give an overview on the biology of AAV vector, discuss the design of AAV-based gene therapy strategies for in vivo applications, and present key achievements and emerging issues in the field. We will use the liver as a model target tissue for gene transfer based on the large amount of data available from preclinical and clinical studies.

[1]  H. Kazazian,et al.  Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. , 2010, Blood.

[2]  R. Samulski,et al.  Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  Percy A. Knolle,et al.  Antigen-presenting cell function in the tolerogenic liver environment , 2010, Nature Reviews Immunology.

[4]  Hojun Li,et al.  Assessing the potential for AAV vector genotoxicity in a murine model. , 2011, Blood.

[5]  Lili Wang,et al.  Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. , 2005, Blood.

[6]  P. Bosma,et al.  A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome , 2016, Molecular therapy. Methods & clinical development.

[7]  R. Scheule,et al.  Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  M. Agbandje-McKenna,et al.  Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion , 2017, Proceedings of the National Academy of Sciences.

[9]  Nathan Morris,et al.  Codon Optimality Is a Major Determinant of mRNA Stability , 2015, Cell.

[10]  S J White,et al.  Promoters and control elements: designing expression cassettes for gene therapy. , 2004, Current gene therapy.

[11]  V. Arruda,et al.  X-linked thrombophilia with a mutant factor IX (factor IX Padua). , 2009, The New England journal of medicine.

[12]  N. Muzyczka,et al.  Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses , 2008, Proceedings of the National Academy of Sciences.

[13]  J. F. Wright,et al.  Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys , 2013, Science Translational Medicine.

[14]  B. Sack,et al.  Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses. , 2010, Human gene therapy.

[15]  B. Wang,et al.  Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy. , 2008, Human Gene Therapy.

[16]  J. Gray,et al.  Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  J. Gray,et al.  Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. , 2007, Blood.

[18]  J. Chamberlain,et al.  Recombinant adeno-associated virus transduction and integration. , 2008, Molecular Therapy.

[19]  R. Herzog,et al.  Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. , 2002, Blood.

[20]  David V. Schaffer,et al.  Engineering adeno-associated viruses for clinical gene therapy , 2014, Nature Reviews Genetics.

[21]  James M. Wilson,et al.  New recombinant serotypes of AAV vectors. , 2005, Current gene therapy.

[22]  R. H. Smith.  Adeno-associated virus integration: virus versus vector , 2008, Gene Therapy.

[23]  T. Nichols,et al.  The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. , 2012, Blood.

[24]  R. Samulski,et al.  Arsenic Trioxide Stabilizes Accumulations of Adeno-Associated Virus Virions at the Perinuclear Region, Increasing Transduction In Vitro and In Vivo , 2013, Journal of Virology.

[25]  Xiaomei Wang,et al.  Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies , 2013, EMBO molecular medicine.

[26]  Min Zhang,et al.  Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease , 2017, Scientific Reports.

[27]  Theresa A. Storm,et al.  Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors , 2000, Nature Biotechnology.

[28]  R. Herzog,et al.  Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Brian K. Kaspar,et al.  Single‐Dose Gene‐Replacement Therapy for Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[30]  M. Kay,et al.  Isolation of Recombinant Adeno-Associated Virus Vector-Cellular DNA Junctions from Mouse Liver , 1999, Journal of Virology.

[31]  R. Samulski,et al.  Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  G. Ronzitti,et al.  77. Antigen-Specific Modulation of Capsid Immunogenicity with Tolerogenic Nanoparticles Results in Successful AAV Vector Readministration , 2016 .

[33]  T. Flotte,et al.  Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for α-1-antitrypsin deficiency , 2017, Proceedings of the National Academy of Sciences.

[34]  Etiena Basner-Tschakarjan,et al.  AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. , 2009, Blood.

[35]  N. HellerKristin,et al.  Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for Dysferlinopathy , 2017 .

[36]  Shoufang Gong,et al.  Short DNA Hairpins Compromise Recombinant Adeno-Associated Virus Genome Homogeneity. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  M. Poncz,et al.  Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype. , 2013, Blood.

[38]  J. Kleinschmidt,et al.  A viral assembly factor promotes AAV2 capsid formation in the nucleolus , 2010, Proceedings of the National Academy of Sciences.

[39]  Zhijian Wu,et al.  Effect of genome size on AAV vector packaging. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  H. Ertl,et al.  Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. , 2013, Blood.

[41]  C. Rice,et al.  Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  K. High.  Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia. , 2003, Transactions of the American Clinical and Climatological Association.

[43]  S. Tapscott,et al.  Immune Responses to rAAV6: The Influence of Canine Parvovirus Vaccination and Neonatal Administration of Viral Vector , 2011, Front. Microbio..

[44]  Marcela V Maus,et al.  CD8+ T-cell responses to adeno-associated virus capsid in humans , 2007, Nature Medicine.

[45]  Geoffrey Kemball-Cook,et al.  Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. , 2006, Blood.

[46]  J. Sommer,et al.  Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. , 2006, Blood.

[47]  A. Nienhuis,et al.  Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[48]  M. Giacca,et al.  Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar Syndrome. , 2014, Human gene therapy.

[49]  O. Christophe,et al.  Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors. , 2017, Blood advances.

[50]  L. Zentilin,et al.  Repeated AAV-mediated gene transfer by serotype switching enables long-lasting therapeutic levels of hUgt1a1 enzyme in a mouse model of Crigler–Najjar Syndrome Type I , 2017, Gene Therapy.

[51]  D. Duan,et al.  Expanding Adeno-associated Viral Vector Capacity: A Tale of Two Vectors , 2007, Biotechnology & genetic engineering reviews.

[52]  S. Zolotukhin,et al.  Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models , 2017, Journal of Translational Medicine.

[53]  I. Alexander,et al.  AAV-encoded OTC activity persisting to adulthood following delivery to newborn spfash mice is insufficient to prevent shRNA-induced hyperammonaemia , 2013, Gene Therapy.

[54]  H. Ertl,et al.  The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. , 2011, Blood.

[55]  M. Agbandje-McKenna,et al.  Mapping the AAV Capsid Host Antibody Response toward the Development of Second Generation Gene Delivery Vectors , 2013, Front. Immunol..

[56]  J. Gray,et al.  expression of human FIX in nonhuman primates of self-complementary AAV vector results in stable therapeutic Safe and efficient transduction of the liver after peripheral vein infusion , 2013 .

[57]  Lili Wang,et al.  Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  J. Orange,et al.  Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. , 2009, The Journal of clinical investigation.

[59]  Lili Wang,et al.  Effects of Self-Complementarity, Codon Optimization, Transgene, and Dose on Liver Transduction with AAV8. , 2016, Human gene therapy methods.

[60]  K. Pratt.  Inhibitory antibodies in hemophilia A , 2012, Current opinion in hematology.

[61]  J. Prieto,et al.  Improvement of Adeno-Associated Virus-Mediated Liver Transduction Efficacy by Regional Administration in Macaca fascicularis. , 2017, Human gene therapy. Clinical development.

[62]  E. Furth,et al.  Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[63]  K. L. La Perle,et al.  Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[64]  D. Duan,et al.  Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. , 2000, The Journal of clinical investigation.

[65]  Balaji Balakrishnan,et al.  Basic biology of adeno-associated virus (AAV) vectors used in gene therapy. , 2014, Current gene therapy.

[66]  N. Srinivasan,et al.  Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo. , 2012, Human gene therapy methods.

[67]  James M. Wilson,et al.  Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. , 2009, The Journal of infectious diseases.

[68]  V. Haurigot,et al.  Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. , 2010, Blood.

[69]  Y. Magami,et al.  Cell proliferation and renewal of normal hepatocytes and bile duct cells in adult mouse liver. , 2002, Liver.

[70]  Yong Huang,et al.  Promoterless gene targeting without nucleases ameliorates haemophilia B in mice , 2014, Nature.

[71]  H. Morizono,et al.  Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents , 2011, Clinical and Vaccine Immunology.

[72]  X. Navarro,et al.  Toxic Effects of Bortezomib on Primary Sensory Neurons and Schwann Cells of Adult Mice , 2015, Neurotoxicity Research.

[73]  F. Mingozzi,et al.  Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial , 2017, Human gene therapy.

[74]  L. Couto,et al.  Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. , 2006, Blood.

[75]  R. Herzog,et al.  Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophilia , 2014, Molecular therapy. Methods & clinical development.

[76]  A. Kemper,et al.  Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia. , 2012, Human gene therapy.

[77]  Jessica Zucman-Rossi,et al.  Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas , 2015, Nature Genetics.

[78]  Lili Wang,et al.  No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[79]  L. Zentilin,et al.  Rescue of bilirubin-induced neonatal lethality in a mouse model of Crigler-Najjar syndrome type I by AAV9-mediated gene transfer , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[80]  M. Bacci,et al.  Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors , 2014, Gene Therapy.

[81]  Xiaopei Huang,et al.  The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. , 2009, The Journal of clinical investigation.

[82]  J. Gray,et al.  transduction of murine and nonhuman primate liver efficient liver-specific human factor IX expression cassette enable highly Self-complementary adeno-associated virus vectors containing a novel , 2013 .

[83]  R. Polishchuk,et al.  Effective delivery of large genes to the retina by dual AAV vectors , 2013, EMBO molecular medicine.

[84]  D. Koeberl,et al.  Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[85]  Daniel G. Anderson,et al.  Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo , 2016, Nature Biotechnology.

[86]  J. Rasko,et al.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response , 2006, Nature Medicine.

[87]  David V Schaffer,et al.  The AAV Vector Toolkit: Poised at the Clinical Crossroads. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[88]  M. Kay,et al.  rAAV-mediated tumorigenesis: still unresolved after an AAV assault. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[89]  Yuqin Wang,et al.  Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. , 2003, The Journal of clinical investigation.

[90]  R. Herzog,et al.  Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. , 2009, Blood.

[91]  R. Rodriguiz,et al.  Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. , 2012, Human gene therapy.

[92]  M. Blüher,et al.  Autophagy determines efficiency of liver‐directed gene therapy with adeno‐associated viral vectors , 2017, Hepatology.

[93]  D. Russell.  AAV loves an active genome , 2003, Nature Genetics.

[94]  Theresa A. Storm,et al.  AAV serotype 2 vectors preferentially integrate into active genes in mice , 2003, Nature Genetics.

[95]  M. S. Chapman,et al.  An essential receptor for adeno-associated virus infection , 2015, Nature.

[96]  C. Leborgne,et al.  Determination of Anti-Adeno-Associated Virus Vector Neutralizing Antibody Titer with an In Vitro Reporter System , 2015, Human gene therapy methods.

[97]  M. Kay,et al.  AAV vectors containing rDNA homology display increased chromosomal integration and transgene persistence. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[98]  F. Bushman,et al.  Recombinant adeno-associated virus integration sites in murine liver after ornithine transcarbamylase gene correction. , 2013, Human gene therapy.

[99]  S. Strom,et al.  Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. , 1998, The New England journal of medicine.

[100]  David A. Scott,et al.  In vivo genome editing using Staphylococcus aureus Cas9 , 2015, Nature.

[101]  C. Reed,et al.  Adeno-Associated Virus Gene Therapy for Liver Disease , 2016 .

[102]  H. Petry,et al.  Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5ch and AAV1. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[103]  L. Kattenhorn,et al.  Adeno-Associated Virus Gene Therapy for Liver Disease , 2016, Human gene therapy.

[104]  S. Chavala,et al.  Oversized AAV transductifon is mediated via a DNA-PKcs-independent, Rad51C-dependent repair pathway. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[105]  R. Kotin.  Large-scale recombinant adeno-associated virus production. , 2011, Human molecular genetics.

[106]  L. Zentilin,et al.  Promoterless gene targeting without nucleases rescues lethality of a Crigler‐Najjar syndrome mouse model , 2017, EMBO molecular medicine.

[107]  C. Leborgne,et al.  Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. , 2010, Human gene therapy.

[108]  K. Rapti,et al.  Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[109]  V. Arruda,et al.  AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. , 2015, Blood.

[110]  J. Grieger,et al.  Adeno-associated virus vectorology, manufacturing, and clinical applications. , 2012, Methods in enzymology.

[111]  H. Kazazian,et al.  Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[112]  P. de Bleser,et al.  Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy. , 2014, Blood.

[113]  M. Ott,et al.  Adeno-Associated Virus Vector–Based Gene Therapy for Monogenetic Metabolic Diseases of the Liver , 2015, Journal of pediatric gastroenterology and nutrition.

[114]  M. Kay,et al.  Selection and evaluation of clinically relevant AAV variants in a xenograft liver model , 2013, Nature.

[115]  Michael Recht,et al.  Long-term safety and efficacy of factor IX gene therapy in hemophilia B. , 2014, The New England journal of medicine.

[116]  J. Mendell,et al.  Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[117]  E. Ayuso,et al.  Production, purification and characterization of adeno-associated vectors. , 2010, Current gene therapy.

[118]  Ru Xiao,et al.  In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector. , 2015, Cell reports.

[119]  A. Galy,et al.  MyD88 Signaling in B Cells Regulates the Production of Th1-dependent Antibodies to AAV , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[120]  N. Srinivasan,et al.  Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo. , 2013, Human gene therapy methods.

[121]  D. Mccarty.  Self-complementary AAV vectors; advances and applications. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[122]  J Montane,et al.  High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency , 2010, Gene Therapy.

[123]  R. Samulski,et al.  Engraftment of a Galactose Receptor Footprint onto Adeno-associated Viral Capsids Improves Transduction Efficiency* , 2013, The Journal of Biological Chemistry.

[124]  J. F. Wright,et al.  Manufacturing and characterizing AAV-based vectors for use in clinical studies , 2008, Gene Therapy.

[125]  D. Duan,et al.  Humoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogs. , 2012, Human gene therapy.

[126]  K. High,et al.  Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[127]  P. Fagone,et al.  Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. , 2013, Blood.

[128]  B. György,et al.  Extracellular vesicles: nature's nanoparticles for improving gene transfer with adeno-associated virus vectors. , 2018, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[129]  M. Kay,et al.  Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. , 2011, The Journal of clinical investigation.

[130]  F. Zoulim,et al.  Hepatitis B virus infection enhances susceptibility toward adeno‐associated viral vector transduction in vitro and in vivo , 2014, Hepatology.

[131]  A. Thrasher,et al.  Codon optimization of human factor VIII cDNAs leads to high-level expression. , 2011, Blood.

[132]  H. Ertl,et al.  Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer , 2015, Journal of Innate Immunity.

[133]  Claus V. Hallwirth,et al.  Identification of liver-specific enhancer–promoter activity in the 3′ untranslated region of the wild-type AAV2 genome , 2017, Nature Genetics.

[134]  Y. Doyon,et al.  Robust ZFN-mediated genome editing in adult hemophilic mice. , 2013, Blood.

[135]  R. Crystal,et al.  Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial , 2017, The Lancet Neurology.

[136]  J. Grieger,et al.  Packaging Capacity of Adeno-Associated Virus Serotypes: Impact of Larger Genomes on Infectivity and Postentry Steps , 2005, Journal of Virology.

[137]  J. Mendell,et al.  Dystrophin immunity in Duchenne's muscular dystrophy. , 2010, The New England journal of medicine.

[138]  Pratima Chowdary,et al.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. , 2011, The New England journal of medicine.

[139]  Lili Wang,et al.  Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. , 2007, Human gene therapy.

[140]  Yang Yang,et al.  A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice , 2016, Nature Biotechnology.

[141]  J. Melvin.  Pompe's disease. , 2000, Archives of neurology.

[142]  K. High.  AAV‐Mediated Gene Transfer for Hemophilia , 2001, Annals of the New York Academy of Sciences.

[143]  C. Dunbar,et al.  Pharmacological Modulation of Humoral Immunity in a Nonhuman Primate Model of AAV Gene Transfer for Hemophilia B , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[144]  J. Sommer,et al.  Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. , 2006, Blood.

[145]  E. Ayuso,et al.  Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. , 2013, The Journal of clinical investigation.

[146]  A. Elkahloun,et al.  Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. , 2015, The Journal of clinical investigation.

[147]  G. Matarese,et al.  Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[148]  Kiran Musunuru,et al.  In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[149]  Jun-Hyeok Choi,et al.  Optimization of AAV expression cassettes to improve packaging capacity and transgene expression in neurons , 2014, Molecular Brain.

[150]  H. Büning,et al.  Adeno-Associated Viral Vectors at the Frontier between Tolerance and Immunity , 2015, Front. Immunol..

[151]  S. Wolbach,et al.  Body Length and Organ Weights of Infants and Children: A Study of the Body Length and Normal Weights of the More Important Vital Organs of the Body between Birth and Twelve Years of Age. , 1933, The American journal of pathology.

[152]  R. Herzog,et al.  Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer. , 2004, Blood.

[153]  M. Bacci,et al.  Improved dual AAV vectors with reduced expression of truncated proteins are safe and effective in the retina of a mouse model of Stargardt disease , 2015, Human molecular genetics.

[154]  T. Conlon,et al.  Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning. , 2015, Human gene therapy. Clinical development.

[155]  Hojun Li,et al.  In vivo genome editing restores hemostasis in a mouse model of hemophilia , 2011, Nature.

[156]  D. Grimm,et al.  Next-generation AAV vectors for clinical use: an ever-accelerating race , 2017, Virus Genes.

[157]  C. Terhorst,et al.  transgene product following hepatic in vivo gene transfer Induction and role of regulatory CD4+CD25+ T cells in tolerance to the , 2013 .

[158]  L. Sullivan,et al.  Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Mean Factor IX Activity Levels of >30% without Immunosuppression , 2016 .

[159]  J. F. Wright,et al.  Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. , 2007, Blood.

[160]  M. Hayden,et al.  Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. , 2006, Human gene therapy.

[161]  Hildegard Büning,et al.  Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution. , 2017, Human gene therapy.

[162]  H. Ertl,et al.  Adeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[163]  R. Samulski,et al.  Adeno-Associated Virus Type 2 (AAV2) Capsid-Specific Cytotoxic T Lymphocytes Eliminate Only Vector-Transduced Cells Coexpressing the AAV2 Capsid In Vivo , 2007, Journal of Virology.

[164]  R. Samulski,et al.  Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia , 2011, Gene Therapy.

[165]  M. Seeliger,et al.  Myosin7a Deficiency Results in Reduced Retinal Activity Which Is Improved by Gene Therapy , 2013, PloS one.

[166]  H. Kazazian,et al.  Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. , 2003, Blood.

[167]  R. Herzog,et al.  Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. , 2007, Blood.

[168]  C. Leborgne,et al.  A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[169]  R. Herzog,et al.  Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[170]  C. Leborgne,et al.  Humoral and Cellular Capsid-Specific Immune Responses to Adeno-Associated Virus Type 1 in Randomized Healthy Donors , 2012, The Journal of Immunology.

[171]  M. Odenthal,et al.  Toll‐like receptor 2–mediated innate immune response in human nonparenchymal liver cells toward adeno‐associated viral vectors , 2012, Hepatology.

[172]  I. Richard,et al.  Prolonged gene expression in muscle is achieved without active immune tolerance using microrRNA 142.3p-regulated rAAV gene transfer. , 2013, Human gene therapy.

[173]  J. Gray,et al.  Enhancing transduction of the liver by adeno-associated viral vectors , 2009, Gene Therapy.

[174]  Lili Wang,et al.  Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. , 2004, Blood.

[175]  J. F. Wright,et al.  Manufacturing and regulatory strategies for clinical AAV2-hRPE65. , 2010, Current gene therapy.

[176]  N. Bourg,et al.  Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. , 2010, Human molecular genetics.

[177]  J. Schlehofer,et al.  Update on the prevalence of serum antibodies (IgG and IgM) to adeno‐associated virus (AAV) , 1999, Journal of medical virology.

[178]  S. Imbeaud,et al.  Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[179]  Lili Wang,et al.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[180]  M. Kay,et al.  Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[181]  Daniel G. Miller,et al.  AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma , 2007, Science.

[182]  Sripriya Ravindra Kumar,et al.  Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain , 2015, Nature Biotechnology.

[183]  Arun K. Srivastava,et al.  Pristimerin enhances recombinant adeno-associated virus vector-mediated transgene expression in human cell lines in vitro and murine hepatocytes in vivo. , 2014, Journal of integrative medicine.

[184]  Qiang Wang,et al.  Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B , 2015, Frontiers of Medicine.

[185]  A. Kamen,et al.  Manufacturing of recombinant adeno‐associated viruses using mammalian expression platforms , 2017, Biotechnology journal.

[186]  P. Bosma,et al.  Mycophenolate mofetil impairs transduction of single-stranded adeno-associated viral vectors. , 2011, Human gene therapy.

[187]  B. Byrne,et al.  Tolerance Induction to Cytoplasmic β-Galactosidase by Hepatic AAV Gene Transfer — Implications for Antigen Presentation and Immunotoxicity , 2009, PloS one.

[188]  M. Kay,et al.  Episomal Persistence of Recombinant Adenoviral Vector Genomes during the Cell Cycle In Vivo , 2003, Journal of Virology.

[189]  K. High,et al.  Overcoming the Host Immune Response to Adeno-Associated Virus Gene Delivery Vectors: The Race Between Clearance, Tolerance, Neutralization, and Escape. , 2017, Annual review of virology.

[190]  B. Byrne,et al.  Transient B Cell Depletion or Improved Transgene Expression by Codon Optimization Promote Tolerance to Factor VIII in Gene Therapy , 2012, PLoS ONE.

[191]  H. Nakai,et al.  Frequency and Spectrum of Genomic Integration of Recombinant Adeno-Associated Virus Serotype 8 Vector in Neonatal Mouse Liver , 2008, Journal of Virology.

[192]  P. Tak,et al.  Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue , 2012, Gene Therapy.

[193]  J. Mendell,et al.  AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal Models , 2015, Annals of clinical and translational neurology.

[194]  H. Nakai,et al.  Characterization of genome integrity for oversized recombinant AAV vector. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[195]  James M. Wilson,et al.  CpG-depleted adeno-associated virus vectors evade immune detection. , 2013, The Journal of clinical investigation.

[196]  F. Mingozzi,et al.  Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions. , 2013, Discovery medicine.

[197]  James M. Wilson,et al.  High-Level Transgene Expression in Nonhuman Primate Liver with Novel Adeno-Associated Virus Serotypes Containing Self-Complementary Genomes , 2006, Journal of Virology.

[198]  Z. Xiang,et al.  Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[199]  Chady H Hakim,et al.  Dual AAV Gene Therapy for Duchenne Muscular Dystrophy with a 7-kb Mini-Dystrophin Gene in the Canine Model. , 2017, Human gene therapy.

[200]  J. Prieto,et al.  Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and Patients. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[201]  Theresa A. Storm,et al.  Extrachromosomal Recombinant Adeno-Associated Virus Vector Genomes Are Primarily Responsible for Stable Liver Transduction In Vivo , 2001, Journal of Virology.

[202]  T. Ohmori,et al.  Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[203]  D. Aubert,et al.  No tumour-initiating risk associated with scAAV transduction in newborn rat liver , 2013, Gene Therapy.